Keros Therapeutics KROS

$ 55.16 1.87%

Quarterly report 2024-Q3
added 11-06-2024

Keros Therapeutics Balance Sheet 2011-2024 | KROS

Annual Balance Sheet Keros Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-317 M	-266 M	-229 M	-265 M	-5.74 M	-22.5 M	-	-	-	-	-	-	-
Long Term Debt	13.4 M	12.8 M	231 K	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	1 M	455 K	862 K	423 K	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	538 K	1.02 M	3.18 M	-	-	-	-	-	-	-
Total Current Liabilities	24.4 M	16.5 M	11.8 M	7.18 M	-	-	-	-	-	-	-	-	-
Total Liabilities	37.8 M	29.4 M	12.1 M	7.72 M	5.5 M	14.7 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	10 M	-	-	-	-	-	-	-
Retained Earnings	-381 M	-228 M	-124 M	-65 M	-19.6 M	-7.31 M	-	-	-	-	-	-	-
Total Assets	370 M	307 M	255 M	269 M	11 M	27.4 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	331 M	279 M	230 M	266 M	7.14 M	-	-	-	-	-	-	-	-
Book Value	332 M	277 M	243 M	262 M	5.45 M	12.8 M	-	-	-	-	-	-	-
Total Shareholders Equity	332 M	277 M	243 M	262 M	-19.4 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Keros Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	17.4 M	12.9 M	13.2 M	13.4 M	13.7 M	14 M	14 M	12.8 M	-	-	-	231 K	453 K	242 K	361 K	476 K	476 K	476 K	476 K	899 K	899 K	899 K	899 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	46.4 M	34.1 M	31.9 M	37.8 M	30.4 M	30 M	29.5 M	29.4 M	11.5 M	-	11.6 M	12.1 M	11.5 M	7.8 M	9.36 M	7.72 M	7.72 M	7.72 M	7.72 M	10.5 M	10.5 M	10.5 M	10.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-523 M	-470 M	-425 M	-381 M	-341 M	-302 M	-264 M	-228 M	-199 M	-	-148 M	-124 M	-117 M	-96.5 M	-80.9 M	-65 M	-65 M	-65 M	-65 M	-19.6 M	-19.6 M	-19.6 M	-19.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	579 M	455 M	486 M	370 M	326 M	356 M	384 M	307 M	253 M	-	235 M	255 M	230 M	243 M	258 M	269 M	269 M	269 M	269 M	11 M	11 M	11 M	11 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	531 M	406 M	442 M	331 M	288 M	322 M	351 M	279 M	239 M	216 M	229 M	230 M	221 M	237 M	255 M	266 M	266 M	266 M	266 M	7.02 M	7.02 M	7.02 M	7.02 M	23.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	533 M	421 M	454 M	332 M	296 M	326 M	355 M	277 M	241 M	-	223 M	243 M	218 M	236 M	248 M	262 M	262 M	262 M	262 M	495 K	495 K	495 K	495 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	533 M	421 M	454 M	332 M	296 M	326 M	355 M	277 M	241 M	211 M	223 M	243 M	218 M	236 M	248 M	262 M	262 M	262 M	262 M	-19.4 M	-19.4 M	-19.4 M	-19.4 M	-7.18 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency